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Summary
Multi-arm trials with follow-up on participants are commonly implemented to assess
treatment effects on a population over the course of the studies. Dropout is an
unavoidable issue especially when the duration of the multi-arm study is long. Its
impact is often ignored at the design stage which may lead to less accurate statistical
conclusions. We develop an optimal design framework for trials with repeated mea-
surements which takes potential dropouts into account, and provide designs for linear
mixed models where the presence of dropouts is noninformative and dependent on
design variables. Our framework is illustrated through redesigning a clinical trial on
Alzheimer’s disease, whereby the benefits of our designs compared with standard
designs are demonstrated through simulations.
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1 INTRODUCTION
Clinical trials often involve several follow-up events for studying the impact of treatment regimes on subjects over the course
of the trial. In recent years, multi-arm designs have become more prominent than separate two-arm trials as the former design
recruits one control group and several treatment arms in a single trial, leading to gains in efficiency for the overall study. However,
the issues caused by the presence of dropouts are unavoidable in multi-arm trials with follow-up, especially when the course of
the study is long. It is common practice to tackle the presence of dropouts by scaling up the effective total sample size of the
study, independently of the design. If the control group has significantly more dropouts than other treatment groups, statistical
inference on pairwise treatment-control comparisons might still be distorted.
Assuming that repeated measurements on the same patients are independent, which may not be realistic, Galbraith et al.1
investigate power calculations for a longitudinal study in the presence of dropouts. In the literature on design of experiments,
some authors2 3 4 5 investigate the robustness of designs to missing values; others account for the presence of missing responses
in the respective design criteria6 7. There are optimal design frameworks for regression models in the presence of responses
missing at random8 9 and in the presence of responses not missing at random10. The attention on a design framework for multi-
arm studies with repeated measurements is rather limited, with only one study taking dropouts into account. However, this
is a longitudinal study with only one group of participants to be followed-up throughout the course of the study5. Assuming
completely observed data, several authors11 12 13 focus on optimal design methodology for linear mixed models with a fixed
number of time points for a longitudinal study.
A key feature of an optimal experimental design is its cost efficiency. For a fixed trial budget, an optimal design will provide
the largest possible amount of information from the data. If a퐷-optimal design assuming all responses will be observed is used,
it has been noted that “. . . researchers can easily compensate for such a small efficiency loss by increasing the sample size by at
most 15%”5. However, in many situations a 15% increase in sample size can already incur considerable extra costs, and there
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are further ways to make a clinical trial design even more efficient. In our investigation, we redesign a study14 assuming a fixed
budget and realistic relative costs of recruiting a new participant versus measuring an existing participant at a further time point,
thus finding the cost-optimal number of time points for the study in addition to the optimal locations of these time points.
We propose an optimal design framework for trials/studies that involve multiple groups of participants and several follow-
up sessions, whereby linear mixed models with some pragmatic design constraints are considered as well as the presence of
dropouts. By definition, a dropout refers to an experimental unit whose information is not being observed further once the
outcome variable on the subject is not being measured at a time point. We consider noninformative dropout that depends on
design variables, such as time of follow-up visits, in our investigation. We assume at the design stage of the study that a linear
mixed model will be fitted to the incomplete data using the available subject data, i.e. all observed responses of subjects during
the study. This missing data analysis approach is appealing for its simplicity of application and as it makes inferences based on
all the observed data. Moreover, likelihood based inference yields valid conclusions in this framework when missing responses
are noninformative15 16 17 18.
Our framework presents a more general approach to finding optimal designs over previously proposed approaches, and allows
differential missingness between different treatment groups. This framework also considers more complex design problems
where a design consists not only of the optimal time points to measure subjects but also of other decision variables such as
the number of time points (if using a fixed cost constraint) and the optimal allocation of dose levels of a drug. We have thus
unified the approaches that consider a single cohort longitudinal study with dropouts5, without dropouts11 and studies with more
than one group of participants13, while additionally incorporating cost and drug dose level considerations. In other words, our
framework could provide optimal designs for longitudinal observational studies as well as for multi-arm studies with follow-
ups. Furthermore, our framework could include more sophisticated and pragmatic design considerations. In an unblinded trial
setting, we investigate the designs where different groups of participants could have different time points versus designs where
everyone is measured at the same time points. This work fills an important gap by incorporating practical design settings in
the framework such that practitioners could find and explore the operating characteristics of various potential optimal designs
before the implementation of a design. In addition, to our knowledge there has been no optimal design framework that seeks
to simultaneously optimise dose levels of a drug together with optimising follow up time point measurements. This is a key
contribution of our work and would be useful for practitioners that seek to both learn about dose-response relationships and
performance of different dose groups over time within a given study.
The structure of this paper is as follows. Section 2 introduces the concept of linear mixed models and the notion of dropout,
as well as depicting the optimal design framework for multi-arm studies that have more than one measurement observed on the
same experimental units over the course of the trial. Section 3 then derives the optimal design framework in the presence of
dropouts. Section 4 revisits a trial on Alzheimer’s disease14 to construct optimal designs through the derived framework, using
the information from the study to elicit the dropout probability functions and the model parameters. Here the main focus is on
finding the design that provides the most information on a fixed budget. We use simulations to compare the performance of the
designs. Section 5 concludes this paper with some discussion and research directions for future work.
2 BACKGROUND AND NOTATIONS
2.1 General linear mixed models
We now present the general formulation of a linear mixed model. Please note, while we define all notation used in the text at
the time of introduction, for convenience we also present a glossary in an Appendix that explains all the notation used within
this paper. Let 퐲푇푖 = (푦푖1, 푦푖2, ..., 푦푖푞) be the 푞 repeated measurements of subject 푖, 푖 = 1, .., 푁 . The responses of subject 푖 can berepresented by the linear mixed model,
퐲푖 = 퐗푖휷 + 퐙푖퐛푖 + 훜푖,
where 휷 is a vector of unknown fixed parameters, 퐗푖 and 퐙푖 are design matrices, 퐛푖 is a vector of unknown random coefficients
that is normally distributed with mean zero and covariance matrix 퐃, i.e. 퐛푖 푖푖푑∼ 푁(ퟎ,퐃), and 훜푖 = (휖푖1, 휖푖2, ..., 휖푖푞)푇 is a vector of
observational errors that is normally distributed with mean zero and covariance matrix 휎2횿, i.e. 훜푖 푖푖푑∼ 푁(ퟎ, 휎2횿). Moreover, 퐛푖
and 훜푖 are assumed to be independent, 푖 = 1,… , 푁 . When we find an optimal design, we conjecture the structure of 횿, leading
to a locally optimal design; see Section 2.4.
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The maximum likelihood method provides an unbiased estimator for the fixed effect parameters 휷 of the linear mixed model,
i.e. 휷̂ =
(∑푁
푖=1퐗
푇
푖 퐕
−1
푖 퐗푖
)−1∑푁
푖=1퐗
푇
푖 퐕
−1
푖 퐲푖,with covariance matrix 풄풐풗(휷̂) =
(∑푁
푖=1퐗
푇
푖 퐕
−1
푖 퐗푖
)−1
,where퐕푖 = 퐙푖퐃퐙푇푖 +휎2횿
is the covariance matrix of 퐲푖 and ∑푁푖=1퐗푇푖 퐕−1푖 퐗푖 is called the Fisher information matrix. Note that this information matrix issumming the individual information that is being contributed by each experimental subject, and can be re-expressed as
푁∑
푖=1
퐗푇푖 퐕
−1
푖 퐗푖 =
푐∑
푘=1
푛푘퐗푇푘퐕
−1
푘 퐗푘 = 푁
푐∑
푘=1
푤푘퐗푇푘퐕
−1
푘 퐗푘, (1)
where we assume units are allocated into 푐 groups with the same values of the design variables in each group. We can then
denote 푋푘 to be the unique design matrix of the 푘th group, where 푘 = 1,… , 푐, with 푛푘 (푤푘 = 푛푘∕푁) reflecting the number
(proportion) of experimental units in group 푘, respectively.
2.2 Dropout mechanisms
We now illustrate the classification of dropout processes19. Let 푦푖푗 denote the 푗푡ℎ measurement taken for subject i, where
푖 = 1,… , 푁 and 푗 = 1,… , 푞. Similarly denote a binary missing data indicator 푙푖푗 where 푙푖푗 = 1 denotes 푦푖푗 is missing and
푙푖푗 = 0 denotes 푦푖푗 is observed. The missing responses are said to be completely random drop-out if 푃 (푙푖푗 = 1) is a constant
∀푖, 푗; random drop-out if 푃 (푙푖푗 = 1) only depends on observed information; and informative drop-out if the drop-out process
depends on unobserved measurements or the missing value itself. The presence of informative drop-out is more complicated
than the presence of other processes and it often requires special treatment and sensitivity analysis based on the incomplete data.
Techniques for the analysis of incomplete data with dropout are available20. We note that the analysis techniques are not the
key interest of our investigation as we focus on finding a design prior to observing a study or an experiment. Nevertheless, the
power of a study would be reduced if the dropout proportion is not accounted for at the design stage of the study.
In this paper, we investigate the role of noninformative, covariate and group dependent dropout processes at the design stage
of a study. Let 푛푘,푗 be the number of subjects in group 푘 who remain in the experiment at time point 푗. A dropout process would
cause 푛푘,1 ⩾ 푛푘,2 ⩾ ... ⩾ 푛푘,푞 . For 푗 < 푞, we have 푔푘,푗 = 푛푘,푗 − 푛푘,푗+1 units who have exactly 푗 measurements observed and 푞 − 푗
measurements missing, and 푔푘,푞 = 푛푘,푞 are the number of subjects with no missing data. At the design stage, the exact rate of
dropout will not be known and so 푛푘,푗 and thus 푔푘,푗 are treated as random variables. In what follows, we denote the probability
of having a response observed on a subject in group 푘 at time point 푗 by 푝푘,표푏푠(푡푘푗 , 훿푘), where 푡푘푗 and 훿푘 are the 푗푡ℎ follow-up
time point and treatment dose of group 푘. The dropout process is noninformative in the sense that it depends on for example
which treatment the subject receives, and at which time point, but not on any unobserved quantity. Denote 퐸[푔푘,푗] by 푚푘,푗 , then
퐸[푔푘,푗] = 푚푘,푗 =
{
푁푤푘 푝푘,표푏푠(푡푘푗 , 훿푘) if 푗 = 푞,
푁푤푘 푝푘,표푏푠(푡푘푗 , 훿푘) −푁푤푘 푝푘,표푏푠(푡푘푗+1, 훿푘) if 푗 < 푞,
(2)
where 푁푤푘 is the number of subjects originally allocated to group 푘. The probabilities {푝푘,표푏푠(푡푘1, 훿푘) −
푝푘,표푏푠(푡푘2, 훿푘), ..., 푝푘,표푏푠(푡푘푞−1, 훿푘) − 푝푘,표푏푠(푡푘2, 훿푘), 푝푘,표푏푠(푡푘푞 , 훿푘)} could be considered as the event probabilities of a multinomial
distribution.
2.3 Optimal design framework
In the absence of missing responses, a design framework for the linear mixed model constructs an optimal design by finding
the setting of design matrix 푿푘 such that a function of the Fisher information defined in (1) is optimized over a design region.
Considering the available subject data used in available case analysis, i.e. all observed responses of subjects who may or may
not dropout at later time points, and the impact of dropouts, the Fisher Information can be written as
푐∑
푘=1
푞∑
푗=1
푔푘,푗푿푇푘[푗]푽
−1
푘[푗]푿푘[푗]
where 푿푘[푗] denotes the sub-design matrix of a subject in group 푘 measured up to the 푗푡ℎ time point. As the Fisher Information
is inversely proportional to the variance-covariance matrix of the model parameters it is common to maximise a function of the
Fisher Informationwhich corresponds tominimising the corresponding function of the variance-covariancematrix. A commonly
used criterion is tomaximise/minimise the determinant of the Information/variance-covariancematrix which is typically referred
4 K. M. Lee ET AL
to as 퐷-optimality. However, at the planning stage of the experiment, the observed values of 푔푘,푗 , 푘 = 1,… , 푐, 푗 = 1,… 푞, are
not available. So we aim to maximize a function of the expected information matrix instead, i.e.
퐸
[ 푐∑
푘=1
푞∑
푗=1
푔푘,푗푿푇푘[푗]푽
−1
푘[푗]푿푘[푗]
]
=
푐∑
푘=1
푞∑
푗=1
푚푘,푗푿푇푘[푗]푽
−1
푘[푗]푿푘[푗].
We note that taking the inverse of this matrix does not give the expected variance-covariance matrix. However, Galbraith et al.1
found that in a single cohort study with equally spaced measurements, this simple approximation gives similar results as more
complicated approximations to the variance-covariance matrix. For moderate to large sample sizes, this was confirmed by Lee
et al.9 for studies without repeated measurements. Also using this simple approximation in a single cohort longitudinal study,
Ortega-Azurduy et al.5 investigated the loss in efficiency of 퐷-optimal designs that were found assuming the complete data set
would be observed, when in fact dropouts occurred. Hence, we will also use the inverse of the expected Fisher information to
approximate the variance-covariance matrix.
Here we propose a more comprehensive design framework for studies with repeated measurements where more than one
group of experimental units are considered in the experiment. This is a common occurrence in most clinical studies where there
will be two or more groups followed up, e.g. placebo and treatment. Sections 2.3.1 and 2.3.2 derive the relevant framework.
2.3.1 Optimal designs when baseline measurements are comparable
In this section we assume that the experimental units are recruited from a homogeneous population where different groups of
units have comparable baseline measurements at the onset of the study. An example of this type of study is to investigate the
efficacy of different treatments over time on subjects who have the same health status. We consider a special case of the linear
mixed model where a group indicator matrix, 푲 푖, is incorporated in the model formulation, giving
퐲푖 = 푿푖푲 푖휷 +풁 푖풃푖 + 흐푖,
as the repeated measurements of subject 푖. In what follows, we refer to this model as 햬푔 . Schmelter13 uses similar models to
find optimal designs for linear mixed models, but does not take dropout into account.
To fix ideas, if there are two groups in an experiment, corresponding to e.g. placebo and an active treatment, and the regression
function is linear in time,햬푔 has 푲 푖 =
(
1 0 0
0 1 0
)
if experimental unit 푖 is in group 1; otherwise 푲 푖 =
(
1 0 0
0 0 1
)
, giving for the
observation at the 푗th time point
(푿푖푲 푖휷)푗 =
{
훽0 + 푡1푗훽1 if experimental unit 푖 is in group 1,
훽0 + 푡2푗훽2 if experimental unit 푖 is in group 2,
with random effects (풁 푖풃푖)푗 = 푏0푖 + 푡푘푗푏1푖, 푘 = 1, 2. The slope parameters 훽1 and 훽2 reflect the effect on responses of group 1
and group 2 respectively due to a unit change in time; (풁 푖풃푖)푗 reflects the response variability of subjects in different groups at
time point 푗.
To construct an optimal design for this special case of the linear mixed model, we seek an optimal design,
휉∗ =
{
풕′ퟏ 풕
′
ퟐ ⋯ 풕
′
풄
푤1 푤2 ⋯ 푤푐
}
, (3)
that optimizes a function of
푐∑
푘=1
푞∑
푗=1
푚푘,푗푲푇푘푿
푇
푘[푗]푽
−1
푘[푗]푿푘[푗]푲푘 (4)
over the design region of possible time points, 픛, and the weights 푤푘, where 풕′풌 = {푡푘1, 푡푘2, ..., 푡푘푞} is the optimal allocation ofunique time points for measuring an outcome variable on group 푘, 푘 = 1, ..., 푐, and 푚푘,푗 , a function of 푤푘, is obtained from (2).
The optimization is subject to the constraints
푡푘1 < 푡푘2 < ... < 푡푘푞 (5)
and
0 ≤ 푤푘 ≤ 1, 푘 = 1,… , 푐,
푐∑
푘=1
푤푘 = 1. (6)
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Note that in order to implement such a design, the weights푤푘, 푘 = 1,… , 푐, may need to be rounded such that푁푤푘 is an integer
for all 푘 = 1,… , 푐. The more relaxed condition (6) is commonly used in the optimal design literature to facilitate numerical
design search. A design found under (6) is referred to as an approximate design, whereas a design where all푁푤푘’s are integers
is called an exact design.
2.3.2 Extension to incorporate additional design variables
In some scenarios, the experimental conditions of different groups are reflected by a continuous explanatory variable 훿 whose
levels can be set by the experimenter. Consider, for example, a treatment that is a dose of a new drug. Although in practice each
participant in the study could have a unique dose level, typically the experimenter would assign individuals to 푐 distinct values
of the dose of the drug including placebo (i.e. when the dose equals 0). We assume the values of the dose can be selected from
within some dose range, e.g. between placebo and maximum tolerated dose. In this situation, the variable ‘dose’ becomes part
of the design, and it may be possible to increase the amount of information to be gleaned from the data by an efficient selection
of the doses as well as the time points. Note that we can also treat all individuals receiving the same value of a dose as belonging
to a group and allow each group’s set of optimal time points to differ, as described in the previous section. In addition, the
probability of observing a response at a given time point may also depend on the dose the patient received. In this section, we
extend our design framework to incorporate this scenario.
In the simplest example, the 푗푡ℎ repeated measurement of subject 푖who is assigned a dose value of 훿푘, where 푘 ∈ {1,… , 푐}, is
푦푖푗 = 훽0 + 푡푘푗훽1 + 훿푘훽2 + 푏0푖 + 푡푘푗푏1푖 + 휖푖푗 ,
where 훽0 is the intercept, 훽1 is the effect on responses of subjects due to a unit change in time, 훽2 is the effect on responses due
to a unit change in dose, and {푏0푖, 푏1푖} are random effects. We refer to this model as 햬푑 . This model can easily be extended to
include, for example, a dose-time interaction effect to incorporate the possibility that different doses may affect the responses
differently over time, but we will consider햬푑 for illustrative purposes in what follows.
Denote the design matrix of this linear mixed model by 퐗푘(푡, 훿). A design problem is then to find
휉∗ =
{
(풕′ퟏ, 훿1) (풕
′
ퟐ, 훿2) ⋯ (풕
′
풄 , 훿푐)
푤1 푤2 ⋯ 푤푐
}
(7)
where the elements, 훿푘, reflect the experimental conditions of group 푘, 푘 = 1, ..., 푐, such that a function of the matrix
푐∑
푘=1
푞∑
푗=1
푚푘,푗푿푇푘[푗](푡, 훿)푽
−1
푘[푗]푿푘[푗](푡, 훿) (8)
is optimized over the design regions, i.e. the design region of time points,픛, and푤푘, the weight for group 푘, as well as the design
region of 훿. Similar to the model in 2.3.1, 푚푘,푗 is obtained from (2), and this design problem is subject to constraints (5) and (6).
2.4 Locally optimal designs
Having chosen the number of groups, 푐, the number of repeated measurements, 푞, and the structure of 푽 푖, the covariance matrix
of 풚푖, for a chosen formulation of the linear mixed model, a design problem is to find the time points of measuring an outcome
variable on the groups and the proportion of units to allocate to each group, such that a function of the corresponding information
matrix is optimized over the design region픛 (and the design region of 훿 if 훿 is also to be optimized in the design problem of the
model introduced in 2.3.2). In practice, the structure of 푽 푖 is not known at the design stage of an experiment. To construct an
optimal design for a future experiment, we employ the notion of locally optimal designs. The structure of 푽 푖 can be estimated
using some historical data or the information that is obtained from some pilot studies. Moreover, the experimenters need to
specify some MAR mechanisms for the different groups prior to finding an optimal design for a study with follow-up/ repeated
measurements.
In addition to the assumption that experimental units are identical and independently distributed, we assume that 훜푖 and 퐛푖 are
independent, and that a first order autoregressive process, AR(1), is chosen for 훜푖 to capture serial correlation. The AR(1) process
has parameter 0 < 휌 < 1 and covariance structure with elements 흍(푡푗 , 푡푗′) = 휌|푡푗−푡푗′ |. This process is often used to model time
series for experiments where observations measured closer together in time are more correlated than those measured further
apart. On the other hand, the random effects 퐛푖 reflect the between person variation, i.e. how individuals behave distinctly in the
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population. By fixing the covariance matrix of 퐛푖, we can find locally optimal group designs for different classes of the above
described linear mixed models.
For example, consider a linear regression model with a random intercept and slope denoted by 풃푖 = (푏0푖, 푏1푖)푇 with covariance
matrix
푫 =
(
푣푎푟(푏0푖) 푐표푣(푏0푖, 푏1푖)
푐표푣(푏0푖, 푏1푖) 푣푎푟(푏1푖)
)
=
(
푑11 푑12
푑12 푑22
)
,
a fixed effects model has a zero matrix for 푫; a random intercept model has 푑11 > 0, 푑22 = 푑12 = 0; a random intercept and
slope model has 푑11 > 0, 푑22 > 0, 푑12 = 0; and a correlated random intercept and slope model has 푑11, 푑22 > 0, 푑12 ≠ 0.
Together with the fixed effects,푿푖푲 푖휷 formodel햬푔 that has the same baselinemeasurements for different groups, or푿푖(푡, 훿)휷
for model 햬푑 where groups additionally depend on a continuous design variable, we can consider the profile of locally opti-
mal time points to measure units’ responses for a range of different 휌 ∈ (0, 1) by optimizing a function of the corresponding
information matrix. We note that often a numerical optimization procedure is required to find a solution to the design problem.
3 OPTIMAL DESIGNS IN THE PRESENCE OF DROPOUTS
The novelty of this work focuses on two aspects when finding a design for a future experiment/ study. Firstly, for a study that
employsmodel햬푔 , we propose to consider two scenarios when finding an optimal design: (1) all experimental units are restricted
to have the same set of time points of measuring the outcome variable, and (2) different groups are allowed to have different sets
of time points of measuring the outcome variable. These can be done by restricting all 풕′풌 to be one set of time points in the designproblem for scenario (1), and setting all sets of 풕′풌 as free variables to be searched in the optimization problem for scenario (2).In other words, the restricted design condition forces the time points in푿푖푲 푖휷 to be the same for all experimental units whereas
the flexible design condition allows the time points in these design matrices to be different for different groups. The former
setting is often used in a blinded trial or longitudinal observational study whereas the latter condition could be implemented in an
open label/ unblinded trial where clinicians and experimental subjects know the administered treatment. Secondly, we propose
to optimise the treatment dose levels for a trial that employs model 햬푑 when the clinicians have the freedom to do so. In this
case, we consider the restricted design condition where all subjects are measured at the same set of time points to conform with
common practice. We note that model햬푔 would not have the flexibility for optimizing the dose levels from a design perspective
when the dropout mechanism depends on both the time point of follow-up measurements and treatment dose level.
In this section, we illustrate these aspects by considering an experiment that has 푐 = 2 and 푞 = 4 in each of the two groups
and that both special cases of the linear mixed model have fixed effects {훽0, 훽1, 훽2} and random effects {푏0푖, 푏1푖}. Note that the
interpretation of the fixed effect parameters for both types of models are different, and that the class of linear mixed model is
determined by the values of the covariance matrix 푫. For each class of the linear mixed model, we employed 푑11 = 1, 푑22 =
3, 푑12 = 0.8
√
3 respectively, unless the model required some (or all of these) to be set to 0, to study the profile of the optimal
time points across a range of 휌 from 0 to 0.9 in steps sizes of 0.1. These values are chosen for ease of comparison with the
literature5. The results presented here are found by using the function fmincon inMatlab, whereby different sets of initial values
are employed to verify the locally optimal design.
3.1 Designs with time dependent dropouts
We now present the application of our design framework for model 햬푔 . An example of a design problem is to find 풕′ퟏ =
(푡11, 푡12, 푡13, 푡14), 풕′ퟐ = (푡21, 푡22, 푡23, 푡24) and푤1, such that the determinant of (4) is maximized over the design region of time points.The design problem is subject to constraints (2), (5), (6) and the flexible/restricted design condition on the time points. Note that
maximizing the determinant of (4) is equivalent to minimizing the determinant of the covariance matrix for the estimator of the
population parameter vector 휷̂ and is defined as 퐷-optimality21.
For better comparability of our results with the literature which did not account for the presence of dropouts11,5, and the
work that investigated the efficiency loss of 퐷-optimal designs due to the presence of dropouts in a longitudinal study with
one cohort5, we consider the standardized time design region [−1, 1] that reflects the interval between follow-up visits in this
illustration. We consider 휎2 = 1, a linear response probability function,
푝1,표푏푠(푡, 훿1) = 0.65 − 0.35푡, (9)
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and a quadratic response probability function,
푝2,표푏푠(푡, 훿2) = 0.5 − 0.35푡 + 0.15푡2, (10)
to capture the presence of missing responses in a group. With this missing mechanism, subjects in group 1 are more likely
to be observed for longer than subjects in group 2. We note that our design framework is compatible with a wide class of
noninformative dropout mechanisms which have monotone response probability functions. We conjecture that the authors5
considered these less commonly used response models for ease of satisfying constraint (2) in the design framework, whereby the
sum of event probabilities must equal to one. When a response model that does not satisfy this constraint over the time design
region is used in our design framework, we resolve this conflict by not optimizing the first two time points whereby they must
be chosen by the experimenter, and truncate the time design region to find 푡푘3, ..., 푡푘푞−1. See Section 3.2 for illustration.
To find the optimal time points, we choose the lower bound of the time design region as the first time point for both groups,
i.e. 푡11 = 푡21 = −1 in this example, because it has the highest response probability rate over the region; and choose the upper
bound as the last time point, i.e. 푡14 = 푡24 = 1, for practical reasons (e.g. pre-selected end of study time). The middle time points
of measuring the outcome variable on the groups and the corresponding weights can be found by using optimization algorithms.
The 푥-axis on the plots in Figure 1 show the second and the third time points of locally 퐷-optimal designs for various
versions of model햬푔 , with quadratic response probability function (10) in one group, and linear response probability function
(9) in the other group. Each plot in Figure 1 corresponds to the middle time points of the optimal designs for each class of the
models; the pair of dotted-lines in the first row of plots correspond to the second and the third time points assuming both groups
are measured at the same set of time points (scenario 1); the two pairs of lines in the second row of plots correspond to the sets
of time points of measuring the outcome variable in each group, which are found assuming these can differ between groups
(scenario 2). The 푦-axis in each plot shows the considered value of 휌 (with 0.1 between each case) in the design problems.
Looking at the trend of the time points, we find that the optimal time points for the experiments with the two response prob-
ability functions do not converge to the equidistant design as 휌 approaches to one, in particular for the model with independent
random intercept and slope parameters, and the model with correlated random intercept and slope parameters. To be more spe-
cific, consider the second row of plots in Figure 1 , we find that the optimal time points of measuring the outcome variable on
the experimental units who remain longer in the study, i.e. the group with the linear response probability function, are larger
than those of the subjects who are expected to be dropping out earlier from the study, i.e. the group with the quadratic response
probability function. Intuitively this is reasonable as we would like to observe units’ follow up measurements before they drop
out. Comparing the first and the second row of plots, we learn that there may be considerable differences between the optimal
time points in different groups that are found under the respective design conditions. Hence when planning a study in practice,
it should be investigated if using different time points for different groups is feasible (e.g. would not violate double-blindness)
since it would increase the amount of information that can be gathered from the data.
We now consider the weights of the locally 퐷-optimal designs for the above described experiment, i.e. the proportions of
experimental units allocated to each group. Table 2 shows the maximum and the minimum weights across the ten considered
cases of 휌, 0 ≤ 휌 ≤ 0.9 (and difference of 0.1 between each case). For the experiments with 휌 > 0, the design framework maxi-
mizes the expected total information by having more experimental units in the group that has a higher response rate within the
time region, i.e. the group that has the linear response probability function (red-dashed line) in the plots in Figure 1 respec-
tively. On the other hand, for the experiment with 휌 = 0 in scenario 1, the locally퐷-optimal designs for the corresponding fixed
effect models and the random intercept models have 푤1 = 0.5 = 푤2. This is because all the experimental units have the same
response rate at the third/ fourth optimal time points, i.e. at the end points of픛 (see the first two plots from the left in the first row
of plots in Figure 1 ). The same reason also applies to the locally 퐷-optimal design for model 햬푔 with fixed effect parameters
and 휌 = 0 in scenario 2 (see the first plot from the left in the second row of plots in Figure 1 ).
3.2 Designs with time and dose dependent dropouts
We now present the application of our design framework for model햬푑 where we have the flexibility to additionally choose the
dose levels, which we treat as comparative groups in the trial, whilst also simultaneously assessing the effect of dose on the
outcome. We restrict 풕′ퟐ = 풕
′
ퟏ in this illustration for ease of presentation, and consider a response model
푝표푏푠(푡, 훿) =
1
1 + 푒푥푝(훾0 + 훾1훿 + 훾2푡)
,
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with 훾1 < 0 and 훾2 > 0, so that the response rate of subjects increases with dose level and decreases with time. In the situation
where the response rate decreases with dose level, we could choose 훾1 > 0 and 훾2 > 0 to reflect the elicitation of the response
rate. Furthermore, we could also include a dose-time interaction in the linear predictor above. The logistic function, while
commonly used in the literature tomodel missingness of responses, would never lead to the event probabilities of themultinomial
distribution in constraint (2) summing to one, or, equivalently, would not result in observing a response at time zero (baseline)
with probability one. We resolve this issue by fixing the second time point of measurements (in addition to the first measurement
at time zero), and truncate the design region to optimize the remaining points 푡푘3, ..., 푡푘푞 , without normalizing them after an
optimal design is found.
As an illustration, consider a one year trial that examines the effect of a drug to treat Alzheimer’s disease14. Patients are
measured five times during the year, with the first measurement taken at baseline, i.e. the start of the trial. We assume without
loss of generality that the dose levels could take values within a range of 0 (placebo) up to 100. We would choose 푡11 = 0
(corresponds to baseline measurement at day 0) and 푡15 = 364 (corresponds to the end of the study), and then fix for example
푡12 = 42 for the first follow-up visit after 1/4 year. The design problem is then to find 풕′ퟏ = (푡13, 푡14) in design region (42, 364),and treatment dose levels 훿1 and 훿2 in [0, 100], such that the determinant of (8) is maximized over this design region, subject to
constraints (2) and (5). If the weight, 푤1, is not fixed to 0.5 in advance, the design problem would also involve finding 푤1 and
푤2 subject to constraint (6). Consider 휎2 = 10, {훾0, 훾1, 훾2} = {0,−3∕100, 3∕364} and the corresponding values for matrix 퐷
that determine the respective classes of linear mixed models. We find optimal designs by choosing 푡15 = 364 to reflect the pre-
selected end of trial time, and 훿2 = 100 as it has the highest response probability rate over the dose region. We find the middle
time points of follow-up measurements, 훿1 and 푤1 (if it was not pre-chosen) using fmincon in Matlab.
Figure 2 shows the 퐷-optimal settings for the above scenario on the 푥-axis of the plot. The first row of plots correspond to
the middle time points of the 퐷-optimal designs for a range of 휌; the second row of plots corresponds to the optimal 훿1; the
third row of plots corresponds to 푤1 for the case in which 푤1 is not pre-selected in the design problem. In all plots, blue solid
lines correspond to the optimal design setting that has optimized 푤1; red dashed lines correspond to the design problem where
푤1 = 0.5. The 푦-axis in each plot shows the value of 휌 (in steps of 0.1) in the design problems.
Looking at the first row of plots, we find that the optimal time points are the same for both designs assuming equal or
unequal weights. Moreover, the optimal time points are far from an equal time interval design that would measure subjects at
approximately {42, 149, 256, 364} days after baseline measurements. If푤1 is not pre-chosen in the design problem, we find that
a 퐷-optimal design has 푤1 < 0.5 and smaller optimal 훿1 when compared to 훿1 of the optimal design that has 푤1 = 0.5. The
former finding agrees with the finding for model햬푔 that in the presence of dropouts, having more subjects from the group that
has a higher response rate would increase the precision of the fixed effect parameters estimation. If we insist in having equal
sample size for both groups, having a larger dose than 0 would hopefully decrease the overall dropout rate of that group.
4 APPLICATION: REDESIGNING A STUDY ON ALZHEIMER’S DISEASE
4.1 Background and exploratory analysis
We now illustrate our framework through an application using the data from the Alzheimer’s disease study14. The study14
considered the effectiveness of two drugs to treat Alzheimer’s disease, donepezil and memantine, as well as receiving both
drugs. The study randomised patients into four groups given by a factorial design, with each group of patients followed up at four
subsequent times after baseline. Each patients had five measurements in each group at week 0, 6, 18, 30, and 52 respectively. The
aim of the study is to explore the changes from baseline measurement in each group over a period of 52 weeks. For illustration
purposes, we only consider the experimental units in the placebo group and the donepezil-memantine (treatment) group, who
were included in the primary intention-to-treat sample. Here we treat the primary outcome measure, SMMSE score (higher
score indicates better cognitive function), as the response variable of our model. The total sample size of the data used in this
illustration is푁 = 144 (72 in each group). By the end of the study period there were only 29 patients in the placebo group and
51 patients in the treatment group included in the per-protocol analysis, with some of them having been lost to follow up during
the course of the study. We consider time in terms of days for both the response probability and the design. The original design,
휉표푟푖, measures subjects at day 42, 126, 210, and 364 after the baseline measurement.
To illustrate our proposed framework we assume an analyst is also interested in investigating the effect of the specific dose
level prescribed to patients on their cognitive function, as well as studying how their cognitive function changes over time in
the different dose groups. This results in adopting model 햬푑 as our analysis model and finding an optimal design accordingly.
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We note that the simpler model 햬푔 could be considered here as well, but this would not allow any optimal dose allocation to
be considered, and could potentially lead to a loss of information in learning about the dose-response relationship. To find an
optimal design, treating dose as a design variable to be optimised, we assume the design will have two dose levels/groups. In
the original design this corresponds to the placebo and the treatment group. Without loss of generality we assume dose can take
values on the interval [0, 100]. We see from the data that the treatment group has less missing data than the placebo group. So
we set the upper optimal dose level to be 훿2 = 100, as was also the case in the previous illustration. The optimal design then
proceeds to find the optimal value of the lower dose level, 훿1, as well as the weight to assign to each dose group, and the optimal
time points at which to take measurements over the one year period. We assume initially that measurements will be taken at five
time points over the one year period (baseline plus four further follow up measurements) and assume that both dose groups will
be observed at the same set of time points. Furthermore, we assume the last measurement will be taken at the end of the trial
period (one year), and that the first follow-up measurement should not be taken too close to the baseline measurement to give
the treatment some time to (potentially) start showing an effect. In particular, we set the time range (in days), in which the three
middle time points must lie, to [42, 364].
As designs are locally optimal, we first use the lme function in the 푅 software package to fit the SMMSE score to the two
groups’ available data (푛1 = 29 in placebo group and 푛2 = 51 in treatment group), to obtain a realistic scenario for which to
design. We consider all four possible classes of model햬푑 and three different temporal correlation structures within each subject:
no correlation, compound symmetry where흍(푡푗 , 푡푗′) = 휌 for 푡푗 ≠ 푡푗′ , and AR(1) as defined in Section 2.4. Table 1 presents AIC
and BIC values from the different models fitted to the data. We find that the random intercept model with AR(1) correlation and
parameter estimates {훽̂0, 훽̂1, 훽̂2} = {8.939,−0.0866, 0.0146}, {휌̂, 푑̂11, 푑̂22, 푑̂12} = {0.3326, 2.6612, 0, 0}, and 휎̂2 = 2.6132 has
the smallest AIC and BIC values among the possible classes of models. To obtain realistic response probability functions for
the two groups, we use the numbers of subjects who remain in the study over the period of 364 days14 to fit logistic regression
models for the two groups where the placebo group has 훿 = 0whereas the treatment group has 훿 = 100. We obtain the following
response probability
푝̂표푏푠(푡푖푗 , 훿) =
1
1 + 푒푥푝(훾̂0 + 훾̂1훿 + 훾̂2푡푖푗)
,
with {훾̂0, 훾̂1, 훾̂2} = {−2.2332,−0.0131, 0.0100}, reflecting that the treatment group has a larger response rate than the placebo
group. These values can then be used to construct optimal designs. The type of fixed and random effects models we have
considered here are commonly used to analyse repeated measurement clinical trial data where there are likely to be dependences
within an individual’s measurements collected over time; see e.g.5. In addition, the logistic model is a commonly used model
to characterise missing data mechanisms (see e.g.22,18 or23), and is a convenient model to use when seeking to fit a regression
model for binary response data.
4.2 Optimal designs, simulation study and sensitivity analysis
We now determine an optimal design using the D-optimality criterion for model햬푑 assuming a random intercept with parameter
values specified above. We denote this design by 휉∗퐷 and it is presented in Table 3 together with the expected number of subjectswho have 푗 observations/measurements, 푚훿,푗 , where 푗 = 1,…5. The design would measure all subjects at 42, 285, 356, 364
days, substantially different to time points used in the original design, denoted by 휉표푟푖 in Table 3 . The design would also allocate
푛1 = 144 ∗ 0.42 ≈ 60 subjects in the placebo group and 푛2 = 144 − 60 =84 subjects in the treatment group, again substantially
different to the allocation used in 휉표푟푖. The design 휉∗퐷 determines 훿1 = 0, i.e. 휉∗퐷 takes the bounds of the dose design region asthe optimal values. This is because a value of 훾1 close to zero was taken when constructing the design and so the optimal design
chooses the bounds of the dose design region in order to maximize the determinant of (8). Nevertheless, in other situations other
dose levels may be determined to be optimal, or it may be the case that the practitioner would like to specify more than two dose
levels for the design e.g. if they think there is a more complex does response relationship, which should then also be reflected
in the choice of model.
In practice, the correct model for the data and true parameter values will not be known in advance of constructing optimal
designs. To address this we perform a sensitivity analysis by considering alternative locally optimal designs based on different
model formulations and parameter values used to construct 휉∗퐷. Table 3 presents designs 휉∗퐷,푅퐼 , 휉∗퐷,푅퐼푆 , and 휉∗퐷,푅퐼푆푐 , which are
퐷-optimal for the values {휌, 푑11, 푑22, 푑12} = {0.3326× 2, (2.661× 2)2, 0, 0}, {0.3326, 2.6612, 2, 0} and {0.3326, 2.6612, 2,−1},
respectively. In other words, these optimal designs correspond to a random intercept model, a linear mixed effect model with
uncorrelated random intercept and slope parameters, and a linearmixed effectmodel where the randomparameters are correlated,
but with parameter estimates different to those obtained from the data. In particular, note that design 휉∗퐷,푅퐼 has the same model
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formulation as 휉∗퐷 but is constructed using a different set of parameters. A similar sensitivity analysis could be done when thedropout mechanism is uncertain, although we do not present the investigation here.
We see that 휉∗퐷,푅퐼 would measure subjects at 42, 292, 349, and 364 days after baseline measurement which is very similar tothe optimal follow up times resulting from 휉∗퐷. The optimal allocation to the two dose groups is also the same under 휉∗퐷,푅퐼 as
휉∗퐷. Both these optimal designs have 푡13 and 푡14 which are very close to the bounds of the time point design region [42, 364],which might suggest that having one fewer time point might be more efficient. This will be explored more in the next section.
When a model with random intercept and slope is considered at the design stage of a study, the 퐷-optimal designs become
qualitatively more different from the former designs. From Table 3 , we see 휉∗퐷,푅퐼푆 and 휉∗퐷,푅퐼푆푐 would measure subjects at 42,46, 154, 364 days after baseline measurements, with both allocating 푛1 = 144 ∗ 0.4865 ≈ 70 subjects in the placebo group and
푛2 = 144 − 70 = 74 subjects in the treatment group. In this example, 휉∗퐷,푅퐼푆 and 휉∗퐷,푅퐼푆푐 are similar as the value of 푑12 = −1is relatively small compared with the variances of the random effects. As with 휉∗퐷, all designs choose the bounds of the dosedesign region, i.e. 훿1 equals 0 in all cases.
We evaluate the performance of different designs through a simulation study. For a given design, we simulate
푦푖푗 = 8.939 − 0.0866푡푖푗 + 0.01458훿푖 + 푏0푖 + 휖푖푗 ,
where 푡푖푗 corresponds to the 푗푡ℎ time point of measuring the outcome variable on subject 푖. Here, 훿푖 = 0 corresponds to the
placebo group, with size 푛1; 훿푖 = 100 corresponds to the treatment group, with size 푛2; 휖푖푗 ∼ 푁(0, 휎̂2흍̂), 흍̂(푡푗 , 푡푗′) = 휌̂|푡푗−푡푗′ |,
and 푏0푖 ∼ 푁(0, 푑̂11). We have thus used model parameters estimated from the data above, and thus design 휉∗퐷 should performbest. Missing values in the vector of observed responses of subject 푖, i.e. 풚푖 = {푦푖1, ..., 푦푖5}, are introduced using a multinomial
indicator with the corresponding event probabilities computed by 푝̂표푏푠(푡푖푗 , 훿) for each group.
For each of the different designs, we repeatedly simulate the incomplete data 100 000 times as described above. For each
incomplete data set, we compute the sample estimates for the fixed effect coefficients, {훽̂0, 훽̂1, 훽̂2} from the available cases. The
elements of 풄풐풗(휷̂) are then estimated empirically using the sample estimates that are obtained from each simulated data set.
Table 4 presents the empirical values of 푣푎푟(훽̂0), 푣푎푟(훽̂1), 푣푎푟(훽̂2) and |풄풐풗(휷̂)| from 100 000 simulated sets, as well as the
퐷-efficiency relative to 휉∗퐷 (five time points), the final column will be explained in the next section. The relative 퐷-efficiency
of a design 휉, with respect to a design 휉∗ is 푅퐸퐷(휉, 휉∗) =
( |퐼휉∗ ||퐼휉 | )1∕푝, where 퐼휉 denotes the covariance matrix provided by usingthe design 휉, and 푝 is the number of fixed effect coefficients in the model.
As designs are obtained using D-optimality we focus on |풄풐풗(휷̂)|. From Table 4 we see that 휉표푟푖 performs poorly with respectto this criterion. We find that the 퐷-efficiency of the original design, 휉표푟푖, relative to 휉∗퐷 is 0.814, implying that approximatelyfive replicates of 휉표푟푖 would be as efficient as four replicates of the 퐷-optimal designs, 휉∗퐷. When an optimal design assumesthe true structure of 퐕푖 but wrong values for 휌 and 푑11, we find that the efficiency loss is not significant; an example of such a
design is 휉∗퐷,푅퐼 that loses only about 0.4% 퐷-efficiency relative to 휉∗퐷 in the simulation. However, if an optimal design assumedthe wrong structure of 퐕푖, the 퐷-efficiency loss could be significant. In our illustration, this loss is about 10% when 휉∗퐷,푅퐼푆 or
휉∗퐷,푅퐼푆푐 is used in the simulation instead of 휉∗퐷. Note however that all the derived designs perform better than the original design,even the ones which have been obtained using a mis-specified model structure. Similar analysis could be conducted to study
efficiency loss when using an optimal design that assumes different non-informative dropout mechanisms.
4.3 Cost saving design
From Table 3 we can see that the derived designs (i.e. designs other than 휉표푟푖) have two follow up time points quite closetogether. For example 휉∗퐷 and 휉∗퐷,푅퐼 have the fourth follow up time point close to the fifth (end of study follow up). There is thusevidence to suggest that a design could have fewer follow up time points without greatly suffering from a loss of information.
From a practical point of view, having fewer follow up time points would reduce the overall cost of the study and thus potentially
allow more patients to be recruited. This may also reduce the chances that subjects may be lost to follow-up.
We illustrate the benefit of employing an optimal design with a fixed budget where the trade off is between the number of
time points of measurement and total sample size. Specifically, we assume that it costs approximately twice as much to recruit
a patient to the study (and take measurements at baseline) as it does to take a follow up measurement. The cost function ratio
used here is a representative example, and was obtained through email communication with one of the authors of the original
DOMINO study who compared testing and cost templates for a number of studies they had previously done and also looked
at the NIHR costing templates. They concluded that despite the variability, the relative cost is approximately 2 to 2.5, i.e. to
recruit a new patient into a study costs about 2 to 2.5 times the cost of an average follow up visit (Prof C. Holmes, personal
K. M. Lee ET AL 13
communication, 20 Feb 2017). Under these conditions, the cost saving afforded from moving from a five time point to a four
time point design (including baseline) allows the possible number of patients to be recruited to the study to increase from 144
to approximately 172. As the costs of recruiting patients and taking follow up measurements should be known in advance of the
trial we do not consider robustness to mis-specification of the cost function here. However, we note that if cost functions are
liable to change during the course of a very long longitudinal study which involves recruiting patients over a substantial period
of time then a sensitivity analysis against different cost functions could be performed and a design chosen accordingly.
The lower panel of Table 3 shows the corresponding 퐷-optimal designs with four time points, but now based on an overall
sample size of 172 patients. In this case, 휉∗퐷,4 would have 푛1 =72 subjects in the placebo group and 푛2 =100 subjects in thetreatment group, with follow up measurements at 42, 319, and 364 days after baseline measurement. The corresponding designs
for 휉∗퐷,푅퐼 , 휉∗퐷,푅퐼푆 , and 휉∗퐷,푅퐼푆푐 , now assuming four time points and a sample size of 172, are also presented here for completeness.As before all designs select the bounds of the dose region, so 훿1 = 0.
We also evaluate the performance of 휉∗퐷,4 in the simulation study. The final column in Table 4 presents the 퐷-efficiency ofall the designs considered relative to 휉∗퐷,4, the optimal design based on four time points and a sample size 172. We see that 휉∗퐷,4outperforms all the competing designs. The original design, 휉표푟푖 would lose about 26% efficiency, the five time point optimaldesigns for a random intercept model, 휉∗퐷 and 휉∗퐷,푅퐼 , would lose about 9% efficiency and 휉∗퐷,푅퐼푆 and 휉∗퐷,푅퐼푆푐 would lose about18% efficiency. The loss of information by having one fewer follow up measurement is more than compensated for by the ability
to increase the sample size which leads to an overall increase in information. The cost ratios used in this analysis are consistent
with typical values associated with multi-arm trials on Alzheimer’s disease. We note that practitioners could implement such
analysis for a range of different cost scenarios to find themost suitable optimal design for implementation. This section highlights
the important role optimal design techniques can play in obtaining the most efficient design, and hence the most information
from the trial under fixed budget constraints.
5 CONCLUSION AND DISCUSSION
We have developed an optimal design framework in the presence of dropouts for a large class of linear mixed models, and have
illustrated our methodology through assessing the optimal designs for two special formulations of the linear mixed model, model
햬푔 and model 햬푑 . In particular, our framework for model 햬푑 allows a design to be constructed which maximises information
about both the dose-response relationship as well as the relationship between different dose groups over time, taking into account
dropout, a hitherto uninvestigated problem. Our framework provides optimal designs for multi-arm studies with follow-ups, and
allows differential non-informative dropout processes for different groups. Our framework accounts for dropout processes that
are dependent on the design variables. This assumption is more realistic since not only time but also the treatment may have an
effect on dropout. Current literature5 11 13 could be viewed as special cases of our framework. Moreover, for model햬푔 , we have
studied two different experimental conditions, i.e. a restricted condition where all experimental subjects must have the same
set of optimal time points of measuring the outcome variable, and a flexible condition that allows for having different sets of
optimal time points of measuring the outcome variable on different groups. We found that in some scenarios where the missing
mechanisms of different groups vary significantly, the flexible designs could be more efficient. So we recommend their use in
practice unless this is prevented by conflicts with secondary objectives of the study or implementation issues such as double
blinding in a clinical trial. We note that this experimental condition could also be considered when finding an optimal design
for model햬푑 .
We have applied our methodology to a real world example by redesigning a clinical trial for Alzheimer’s disease14. To this
end, we investigated the design problem from two different angles. First, we generated optimal designs for the exact scenario
(five time points) of the trial under consideration and found that if an optimal design had been employed in the original study,
almost 19% of the experimental effort (and thus experimental costs) could have been saved while obtaining the same amount
of information from the resulting data. The optimal designs for this scenario had several time points clustered relatively close
together, which may be impractical (repeated visits to the clinic at short time intervals). This suggested that we may not need
five time points for the trial. Hence, we investigated this problem within a cost-efficiency framework, and found that optimal
designs with four time points and increased sample size such that the overall cost of the trial is kept fixed can lead to more
efficient designs, and thus more information to be gleaned from the data.
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We have illustrated our methodology using퐷-optimality, as one of the most commonly used optimality criteria, which reflects
a situation where there is equal interest in estimating all mean model parameters accurately while treating the variance com-
ponents as nuisance parameters. In practice, the criterion that best reflects the purpose of the experiment should be chosen. If
there is more than one such objective, a compound criterion can be selected. In all these cases, our methodology can be followed
analogously, with the obvious adjustments to the numerical design search routine.
We have shown that the presence of dropouts has considerable impact on the locally optimal designs for studies involving
multiple comparison groups and several follow-up sessions. Only locally optimal designs are available for the linear mixed
models as the dropout processes and the covariance structure of the repeated measurements are unknown at the design stage of
an experiment. Nevertheless, locally optimal designs are important as benchmarks, against which all other candidate designs can
be assessed. Using data from historical/pilot studies, we can estimate the covariance structure as well as the dropout processes
for constructing an optimal design for a future study. In our investigations, we assume an AR(1) process for the observational
errors of the experimental subjects to capture the within-subject correlation. By trying different sets of values for the variance of
random coefficients, we find that the structure of 푫, i.e. the covariance matrix of random coefficients, rather than the values of
its elements has more impact on the trends of the optimal time points across the range of realistic values for the serial correlation
parameter 휌. Section 4 illustrated the sensitivity analysis of different locally optimal designs using simulation. We note that
further robustness checks could be performed depending on the context. These include, robustness to mis-specification of the
missing data mechanism, mis-specification of the serial correlation structure of the errors in the repeated measurements, and
mis-specification of the covariance structure of random coefficients. If sensitivity analyses flag up a lack of robustness to different
parameter values or models, a way to address this could be through an extension of our framework to Bayesian24 designs or
maximin efficient12 designs.
For finding optimal designs, we have combined the concepts of cost functions based on financial considerations and patient
drop-out based on time and treatment. It might be interesting to also factor in a willingness to come function, potentially based on
the total number and on the frequency of visits. This could be estimated using historical trial data or a questionnaire administered
prior to the start of the trial. For example, some patients may find a large number of visits or visits within a few weeks of each
other excessive, and may be less likely to attend all of them.
It has been our primary intention to propose a flexible framework for trial designs that allows the possibility for different
arms to have different designs. From our point of view, blinded trials could be less efficient than the flexible design that has
different schedules for different groups, in terms of collecting sufficient observations given the same resources and potentially
different dropout mechanisms. In this context, the flexible design can be viewed as a benchmark – the best we can achieve, but
not necessarily applicable in practice. Simulation studies could be conducted to investigate the information loss of the restricted
design for blinded trials, which might be negligible especially when the dropout mechanisms of the two groups have similar
characteristics. We recognise that, apart from blinding, there may be further reasons for restricting both groups to have the same
treatment regimen, e.g. when interim analyses are planned or when testing certain underlying assumptions between the two
groups. We would argue that if this was of primary interest then this should be reflected in the optimality criterion, ultimately
leading to a different design. We do note that there is literature that suggests that using a linear mixed model would not be
adversely impacted by different designs in the different arms, such as if there were unequal time points, e.g. see Hickey et al25.
For future research, we suggest considering the impact of an intermittent missing data pattern on the optimal designs for linear
mixed models. It may also be interesting to relax the usual convention (see, e.g.5) of automatically selecting the pre-specified
end of trial as the latest time point for measurements. In particular in the situation where dropout is high, an optimal design may
select an earlier time point to be the last time point, so that more responses could be observed at this earlier time than at the end
of the trial. This could be a feature of an adaptive trial in which the design could be adapted based on interim analysis. In this
case, the design framework would need to be extended to include interim updates on the model parameters and hence update
the design. Feasibility of this approach would, of course, depend on the research question of the trial.
We note that other missing data analysis approaches, such as multiple imputation or pattern mixture models17, could also
be applied to the longitudinal data for making inferences. Developing a design framework for these approaches would be sub-
stantially more challenging. These problems have not even been tackled yet for the simpler setting of fixed effects models. A
further interesting extension of our work would be to consider generalized linear mixed models in the presence of dropouts.
The key challenge to considering these suggestions is to find (a good approximation to) the expected information matrix (or to
the covariance matrix) for the corresponding models, having accounted for the features of the missing data analysis approach
at the design stage of an experiment. Furthermore, more sophisticated optimization algorithms might be required to solve the
potentially considerably more complex optimization problems.
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FE FE CS FE AR(1) RI RI CS RI AR(1) RIRS RIRS CS RIRS AR(1)
AIC 2171.89 1972.30 1969.32 1972.30 1974.30 1961.31 1967.65 1969.65 1962.80
BIC 2187.73 1992.10 1989.12 1992.10 1998.06 1985.07 1991.41 1997.37 1990.53
TABLE 1 AIC and BIC values for the different models fitted to the data in Section 4.1. Compound Symmetry (CS) and AR(1)
refer to the serial correlation structure within subjects over time.
TABLE 2 Maximum/minimum optimal weight, 푤1, for the group with quadratic response, found under the restricted and the
flexible design condition, respectively, for model햬푔 (corresponds to the optimal designs in Figure 1 ).
Flexible Restricted
Max 푤1 Min 푤1 Max 푤1 Min 푤1
FE 0.5000∗ 0.4821 0.5000∗ 0.4828
RI 0.4981 0.4901 0.5000∗ 0.4878
RIRS 0.4921 0.4624 0.4921 0.4781
RIRSc 0.4907 0.4761 0.4907 0.4773
∗ These maximum weights are obtained for 휌 = 0.
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TABLE 3 Middle time points of 퐷-optimal designs for several classes of model 햬푑 , 푡11 = 푡21 = 0, 푡12 = 푡22 = 42, 푡15 = 푡25 =
364,푤2 = 1−푤1. The optimal values of 훿 are the bounds of the design region [0, 100],푤1 is the optimal weight of the placebo
group (훿1 = 0). Both groups are measured at the same time points, 푚훿=푘,푗 , 푘 = {0, 100}, 푗 = 1, ..., 5 is the expected number of
subjects in group 푘 who have exactly 푗 observed responses.
푡11 푡12 푡13 푡14 푡15 푤1
푚훿=0,1 푚훿=0,2 푚훿=0,3 푚훿=0,4 푚훿=0,5 푛1
푚훿=100,1 푚훿=100,2 푚훿=100,3 푚훿=100,4 푚훿=100,5 푛2
Five time point design,푁 = 144
휉표푟푖 0 42 126 210 364 0.5placebo group 10 10 14 24 14 72
treatment group 3 4 7 24 34 72
휉∗퐷 0 42 285.2340 355.6943 364 0.4221placebo group 8 31 8 1 12 60
treatment group 4 24 14 2 40 84
휉∗퐷,푅퐼 0 42 292.2367 349.1291 364 0.4189
placebo group 8 32 7 1 12 60
treatment group 3 26 12 3 40 84
휉∗퐷,푅퐼푆 0 42 46.3915 153.7180 364 0.4865
placebo group 10 0 13 33 14 70
treatment group 3 0 6 30 35 74
휉∗퐷,푅퐼푆푐 0 42 46.3841 153.8501 364 0.4865
placebo group 10 0 13 33 14 70
treatment group 3 0 6 30 35 74
Four time point design,푁 = 172
휉∗퐷,4 0 42 318.5670 364 0.4183
placebo group 10 42 6 14 72
treatment group 4 37 11 48 100
휉∗퐷,푅퐼 0 42 322.3673 364 0.4154
placebo group 10 42 5 14 71
treatment group 4 38 11 48 101
휉∗퐷,푅퐼푆 0 42 137.3887 364 0.4865
placebo group 12 13 43 16 84
treatment group 4 5 37 42 88
휉∗퐷,푅퐼푆푐 0 42 136.9573 364 0.4865
placebo group 12 13 43 16 84
treatment group 4 5 37 42 88
TABLE 4 Simulation output of design comparison.
푣푎푟(훽̂0) 푣푎푟(훽̂1) 푣푎푟(훽̂2) |풄풐풗(휷̂)| 푅퐸퐷(휉, 휉∗퐷) 푅퐸퐷(휉, 휉∗퐷,4)
×10−1 ×10−7 ×10−5 ×10−12
휉표푟푖,푁 = 144 1.524 18.06 2.104 2.828 0.8140 0.7448
휉∗퐷,푁 = 144 1.736 8.146 2.815 1.526 1 0.9150
휉∗퐷,푅퐼 ,푁 = 144 1.745 8.175 2.829 1.544 0.9959 0.9113
휉∗퐷,푅퐼푆 ,푁 = 144 1.385 13.17 2.540 2.099 0.8990 0.8226
휉∗퐷,4,푁 = 172 1.477 8.440 2.433 1.169 1.093 1
휉∗퐷,푅퐼푆 and 휉∗퐷,푅퐼푆푐 are identical in this illustration.
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APPENDIX - GLOSSARY
Table 5 presents an explanation for the notation used in the paper. Table 6 gives the details of the class of models considered
in the paper. Table 7 explains the restricted and flexible design conditions. Tables 8 and 9 explain the definition of models
햬푔 and햬푑 , respectively.
Notation Definition Assumption
퐲푇푖 = (푦푖1, 푦푖2, ..., 푦푖푞) 푞 repeated measurements of subject 푖. There are푁 subjects: 푖 = 1, .., 푁
훿푘 Treatment dose of group 푘. Could be continuous or categorical. The
number of groups, 푐, is pre-specified.
풕′풌 = {푡푘1, 푡푘2, ..., 푡푘푞} A vector of 푞 time points of a subject ingroup 푘.
The number of time points, 푞, is pre-
specified. 푡푘1 < 푡푘2 < ... < 푡푘푞
푤푘 Proportion of subjects in group 푘 0 ≤ 푤푘 ≤ 1,∑푐푘=1푤푘 = 1.
휷 A vector of fixed effect parameters Unknown values that are estimated by the
maximum likelihood method.
퐗푖 (Fixed effect) design matrix of subject 푖 Could depend on 풕′풌 and 훿푘.
퐙푖 (Random effect) design matrix of subject 푖. Could depend on 풕′풌 and 훿푘.
퐛푖 A vector of random effect parameters of
subject 푖.
퐛푖 follows a multivariate normal distribu-
tion with mean zero and covariance matrix
퐃; 퐛푖, 푖 = 1, ..., 푁 , are independent and
identically distributed.
퐃 Covariance matrix of random coefficients
퐛푖.
Can be conjectured at design stage, using
e.g. historical studies.
훜푖 Avector of observational errors of repeated
measurements on subject 푖.
훜푖 follows a multivariate normal distribu-
tion with mean zero and covariance matrix
휎2횿; 훜푖, 푖 = 1, ..., 푁 , are independent and
identically distributed, and are independent
of 퐛푖, 푖 = 1, ..., 푁 .
휎2횿 Covariance matrix of observational errors
of repeated measurements
Can be conjectured at design stage, using
e.g. historical studies.
퐕푖 = 퐙푖퐃퐙푇푖 + 휎
2횿 Covariance matrix of 퐲푖
푝푘,표푏푠(푡푘푗 , 훿푘) Probability of having a response observed
on a subject in group 푘 at time point 푗.
Could depend on 풕′풌 and 훿푘. Can be conjec-tured at design stage, using e.g. historical
studies.
푔푘,푗 Number of subjects in group 푘 who have
exactly 푗 repeated measurements
Unknown at design stage
푚푘,푗 = 퐸[푔푘,푗] Expected number of subjects in group 푘
who have exactly 푗 repeated measurements
Could depend on 풕′풌 and 훿푘.
휉∗퐷,푚 퐷-optimal design for a class of modeldenoted by m
Maximises the determinant of the informa-
tion matrix of m.
TABLE 5 Notation used in the paper.
How to cite this article: K.M. Lee, S. Biedermann, and R. Mitra (2018), D-optimal designs for multi-arm trials with dropouts,
Statistics in Medicine, 2018;00:1–16.
20 K. M. Lee ET AL
Class of models with random effect parameters, 풃푖 = (푏0푖, 푏1푖)푇 ,
which have covariance matrix 푫 =
(
푣푎푟(푏0푖) 푐표푣(푏0푖, 푏1푖)
푐표푣(푏0푖, 푏1푖) 푣푎푟(푏1푖)
)
=
(
푑11 푑12
푑12 푑22
)
Fixed effects model: Random intercept
model:
Random intercept and slope
model:
Correlated random intercept and
slope model:
푑11 = 푑22 = 푑12 = 0 푑11 > 0, 푑22 = 푑12 =
0
푑11 > 0, 푑22 > 0, 푑12 = 0 푑11, 푑22 > 0, 푑12 ≠ 0
TABLE 6 Details of the statistical models considered in the paper.
Restricted design condition Flexible design condition
풕′풌 are the same ∀푘, 푘 = 1,… , 푐. 풕
′
풌 could be different.All subjects are measured at the same time. Different groups of subjects aremeasured at different time
points.
Suitable for longitudinal studies or blinded trials. Only suitable for open label or unblinded trials
Simpler in terms of logistic and administrative arrange-
ments.
Requires different arrangements for different groups.
Less observations might be collected especially when the
response rates of the groups are significantly different.
More information could be collected in particularly when
time is the major factor that causes dropout.
TABLE 7 Explanation of the restricted and flexible design conditions used in the paper.
Notation Definition/Usage
햬푔 퐲푖 = 푿푖푲 푖휷 +풁 푖풃푖 + 흐푖, where 푲 푖 is a group indicator matrix.
• For studies that have comparable baseline measurements, and aim to investigate time effect on
different groups.
• Information matrix in the presence of time dependent dropouts is∑푐
푘=1
∑푞
푗=1 푚푘,푗푲
푇
푘푿
푇
푘[푗]푽
−1
푘[푗]푿푘[푗]푲푘.
• Design problem is to choose 풕′풌 and 푤푘.
• Section 3.1: Illustration example with 푐 = 2, 푞 = 4. One group has a quadratic 푝1,표푏푠(푡1푗 , 훿1) and the
other has a linear 푝2,표푏푠(푡2푗 , 훿2) response probability function. Both response probabilities depend only
on the time points. We consider cases with AR(1) serial correlation which have different values of 휌,
0 ≤ 휌 ≤ 0.9 (and difference of 0.1 between each case) and 휎2 = 1. Standardised time design region
[-1, 1] that reflects the interval between follow-up visits.
• Models in illustration have 푑11 = 1, 푑22 = 3, 푑12 = 0.8
√
3 unless the models required some (or all
of these) to be set to 0.
• Figure 1 shows the 퐷-optimal time points with restricted design condition (top row) and flexible
design condition (bottom row) respectively.
• Table 2 shows the maximum and the minimum weights across the ten considered cases of 휌. For
휌 > 0, 퐷-optimal designs generally have more experimental units in the group that has a higher
response rate within the time region.
TABLE 8 Definition of model햬푔 .
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Notation Definition/Usage
햬푑 푦푖푗 = 훽0 + 푡푘푗훽1 + 훿푘훽2 + 푏0푖 + 푡푘푗푏1푖 + 휖푖푗
• For studies that investigate time effect and treatment effect on the population.
• Information matrix in the presence of dropouts is∑푐푘=1∑푞푗=1 푚푘,푗푿푇푘[푗](푡, 훿)푽 −1푘[푗]푿푘[푗](푡, 훿)
• Design problem is to choose 훿푘, 풕′풌 and 푤푘.
• Section 3.2: Illustration example with 푐 = 2, 푞 = 5, and a logistic function for response probability
that depends on time point and dose level. We consider cases with AR(1) serial correlation which
have different values of 휌, 0 ≤ 휌 ≤ 0.9 (and difference of 0.1 between each case) and 휎2 = 10. The
design region for 훿푘 is [0, 100] and time region is [0, 365] days.
• Models in the illustration have 푑11 = 1, 푑22 = 3, 푑12 = 0.8
√
3 unless the models required some
(or all of these) to be set to 0. Figure 2 shows the 퐷-optimal time points (first row), optimal dose
(second row), and optimal weight (third row), with restricted design condition.
• Section 4 shows how to verify some potential optimal designs for a case study. Table 3 presents the
퐷-optimal time points and weights for various version of this model, that have five time points and
four time points respectively. Table 4 shows the simulation performance of the design candidates.
• Models in Section 4 consider {휌̂, 푑̂11, 푑̂22, 푑̂12} = {0.3326, 2.6612, 0, 0}, {0.3326 × 2, (2.661 ×
2)2, 0, 0}, {0.3326, 2.6612, 2, 0} and {0.3326, 2.6612, 2,−1}, respectively .
TABLE 9 Definition of model햬푑 .
